Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.5%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (93.4% of net sales) and other (6.6%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.5%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (74.1%), Europe (17%) and other (8.9%).
Number of employees : 13 600 people.
2019 2020 Delta USD (in Million) % USD (in Million) % Innovative Medicines 22,449 100.6% 24,689 100.2% +9.98%
2019 2020 Delta USD (in Million) % USD (in Million) % United States 16,645 74.6% 18,217 73.9% +9.44% Europe 3,811 17.1% 4,135 16.8% +8.5% Other International 1,993 8.9% 2,337 9.5% +17.26%
Vote Quantity Free-Float Company-owned shares Total Float
Stock A
1
1,256,593,156
1,252,149,307
99.6% 0
0.0% 99.6%
Shareholders Gilead Sciences, Inc. (US) Gilead Sciences, Inc. (BRGILDBDR000)
Name Equities % Capital Research & Management Co. (Global Investors) 121,672,399
9.71% The Vanguard Group, Inc. 97,128,178
7.75% Capital Research & Management Co. 64,780,000
5.17% SSgA Funds Management, Inc. 55,206,559
4.40% Capital Research & Management Co. (International Investors) 46,548,996
3.71% Capital Research & Management Co. (World Investors) 38,534,588
3.07% BlackRock Fund Advisors 31,581,841
2.52% Geode Capital Management LLC 20,078,920
1.60% Dodge & Cox 17,107,888
1.36% Northern Trust Investments, Inc.(Investment Management) 15,243,829
1.22%
Name Equities % Caixa Econômica Federal 24,200
0.0010% Bram Bradesco Asset Management S/A DTVM 1,550
0.0001% Infinity Asset Management Administração de Recursos Ltda. 650
0.0000%
Name Equities % Valuation
Galapagos NV (GLPG) 16,707,477 25.5% 1,746,432,571 USD Arcus Biosciences, Inc. (RCUS) 13,913,029 21.4% 483,199,497 USD Allogene Therapeutics, Inc. (ALLO) 7,486,689 5.34% 259,788,108 USD Jounce Therapeutics, Inc. (JNCE) 5,539,727 13.9% 62,598,915 USD Agenus Inc. (AGEN) 11,111,111 5.84% 40,888,888 USD HOOKIPA Pharma Inc. (HOOK) 2,092,799 8.12% 22,372,021 USD Sierra Oncology, Inc. (SRRA) 348,017 3.15% 5,039,286 USD
-
- Nasdaq Global Select Market
- Nasdaq 100 / S&P 100, S&P 500, Stoxx Americas 100, Stoxx Global 200
- Bloomberg Code :
GILD:US
- Reuters Code :
GILD.O
- Datastream Code :
@GILD
Company contact information
Gilead Sciences, Inc.
333 Lakeside Drive
CA 94404 San Mateo, California
Phone : +1 650 574 3000
Fax : +1 650 578 9264
web site :
http://www.gilead.com
Gilead Sciences : raises 2020 profit forecast on remdesivir strength
Sector Bio Therapeutic Drugs
Connections : Gilead Sciences, Inc.
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
